Trimetazidine Hydrochloride Tablets

Belonging to other anti-anginal cardiovascular drugs, trimetazidine protects the energy metabolism of cells under hypoxia or ischemia, prevents the decline of intracellular ATP levels, thereby ensuring the normal function of ion pumps and the normal operation of transmembrane sodium-potassium flow, and maintaining the stability of the intracellular environment. Animal studies: trimetazidine: 1 Helps maintain the energy metabolism of the heart and nerve sensory organs under ischemia and hypoxia. 2 Reduces intracellular acidosis and changes in transmembrane ion flow caused by ischemia. 3 Reduces the movement and infiltration of multinuclear neutrophils during ischemia and myocardial reperfusion, and reduces the scope of experimental infarction. 4 While producing this effect, it has no significant effect on hemodynamics. Human studies: Controlled experiments on patients with angina pectoris showed that trimetazidine can: 1 Increase coronary blood flow reserve, thereby delaying the occurrence of exercise-induced ischemia from the 15th day of treatment. 2 Limits rapid fluctuations in blood pressure without significant changes in heart rate. 3 Significantly reduces the frequency of angina attacks. 4 Significantly reduces the use of glyceryl trinitrate.

The main ingredient of this product is trimetazidine hydrochloride.

This product is a film-coated tablet, which appears white after removing the film coating.

Preventive treatment of angina attacks and auxiliary symptomatic treatment of vertigo and tinnitus.

60 mg/24 hours: 1 tablet 3 times a day, taken with meals.

Rarely, gastrointestinal discomfort (nausea, vomiting). Due to the presence of the excipients sunset yellow FCFS (E110) and carmine red A (E124), there is a risk of allergic reactions.

Animal studies have not shown teratogenic effects. However, due to the lack of clinical data, the risk of teratogenicity cannot be completely ruled out. Administration should be avoided during pregnancy. Due to the lack of information on whether it is secreted in breast milk, it is recommended not to breastfeed during treatment.

Precautions for children: The safety and effectiveness of the drug for children have not been determined. Precautions for pregnancy and lactation: Avoid administration during pregnancy. It is recommended not to breastfeed during treatment. Precautions for the elderly: See other items or follow the doctor's advice.

To avoid possible interactions between different medicines, you must tell your doctor or pharmacist about other treatments you are receiving.

Sealed, store in a dry place.

20mg

36 months

Suzhou Pharmaceutical Factory

• Founded in:

  2006-02-14

• Address:

  No. 2-1, Dongwu South Road, Wuzhong District, Suzhou City

• Tax NO.:

  91320506138170408U

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view